Mizuho Securities USA LLC Has $2.66 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

Mizuho Securities USA LLC cut its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 20.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,230 shares of the medical research company's stock after selling 2,818 shares during the quarter. Mizuho Securities USA LLC's holdings in IQVIA were worth $2,661,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. First Foundation Advisors boosted its position in IQVIA by 3.8% during the second quarter. First Foundation Advisors now owns 1,161 shares of the medical research company's stock worth $245,000 after acquiring an additional 43 shares during the last quarter. Invera Wealth Advisors LLC raised its stake in IQVIA by 0.3% during the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company's stock worth $3,183,000 after purchasing an additional 46 shares during the period. Covestor Ltd raised its stake in IQVIA by 45.3% during the first quarter. Covestor Ltd now owns 154 shares of the medical research company's stock worth $39,000 after purchasing an additional 48 shares during the period. Oregon Public Employees Retirement Fund raised its stake in IQVIA by 0.3% during the second quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company's stock worth $3,313,000 after purchasing an additional 48 shares during the period. Finally, Continuum Advisory LLC raised its stake in IQVIA by 3.3% during the second quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company's stock worth $325,000 after purchasing an additional 49 shares during the period. Institutional investors and hedge funds own 89.62% of the company's stock.

Insider Buying and Selling at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the business's stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. The trade was a 6.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.60% of the company's stock.

IQVIA Trading Up 2.1 %

IQVIA stock traded up $4.22 during midday trading on Friday, hitting $201.82. 1,887,846 shares of the stock were exchanged, compared to its average volume of 2,206,617. The company has a fifty day simple moving average of $222.67 and a two-hundred day simple moving average of $227.18. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The stock has a market capitalization of $36.63 billion, a PE ratio of 26.49, a P/E/G ratio of 2.03 and a beta of 1.51. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Barclays cut their price target on shares of IQVIA from $260.00 to $255.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. Argus raised shares of IQVIA to a "strong-buy" rating in a research note on Wednesday, July 31st. TD Cowen cut their target price on shares of IQVIA from $270.00 to $255.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. JPMorgan Chase & Co. cut their target price on shares of IQVIA from $279.00 to $240.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 5th. Finally, Leerink Partners reissued an "outperform" rating and issued a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research note on Tuesday. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $256.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.